Protalix (PLX -3.7%) slips after being downgraded to Market Perform at Wells Fargo, citing the CHMP's rejection of Elelyso - despite the drug's favorable benefits - in deference to Shire's Orphan exclusivity status for Vpriv. The firm also lowers its price range to $6 - $8 from $9 - $11.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs